Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
ASCO 2022
It was a pleasure to catch up with @LesokhinMD of @MSKCancerCenter at #ASH25 to hear about a post-hoc analysis of the MagnetisMM-3 trial evaluating the feasibility & safety of prolonged elranatamab interruption in R/R #myeloma.
Watch here: 👉
#MMSM
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis
In this video, Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the results of ...
ow.ly
🎥 Adlette Inati of @lebamericanuni presents findings from the first cohort of the ongoing Phase I/II HIBISCUS Kids study, which investigates the PK activator etavopivat in children & adolescents with #SickleCellDisease:
👉 👈
#ASH25 #Hematology #CTSM
Safety and efficacy of etavopivat in adolescents with SCD: the ongoing HIBISCUS Kids trial
Adlette Inati, MD, Lebanese American University, Blat, Lebanon, discusses safety and efficacy findings from the first ...
ow.ly
Watch our interview from #ASH25 with Lynette Chee of @PeterMacCC to hear updated results from an ongoing Phase II trial of elritercept in patients with transfusion-dependent LR-MDS.🩸
Click here: 👉
#MDSsm #CTSM #TrialUpdate #HemOnc
Updated results from a Phase II trial of elritercept in LR-MDS
Lynette Chee, MBBS, PhD, The Royal Melbourne Hospital/Peter MacCallum Cancer Centre, Melbourne, Australia, shares updated ...
ow.ly
Our latest podcast dives into key multiple myeloma updates from #ASH25 🩸
From redefining functional high-risk disease to CAR-T and T-cell engagers.
🎧 Listen here:
Featuring Luciano Costa (@End_myeloma), Nisha Joseph (@nishjo76), Shambavi Richard,
Top updates in myeloma from ASH 2025: the RedirecTT-1 and MajesTEC-3 trials, dual-targeting CAR-T,...
This podcast features key updates in multiple myeloma from ASH 2025. Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham,...
ow.ly
Could progression of disease within 36 months (POD36) of starting first-line targeted therapy be used as a clinical tool to identify high-risk patients with CLL?🩸
@hampel_p of @MayoClinic provides insight into this in a video interview from #ASH25:
🎥
POD36 as a prognostic marker and clinical tool in frontline CLL
In this interview, Paul Hampel, MD, Mayo Clinic, Rochester, MN, highlights that progression of disease within 36 mon...
ow.ly
ASCO 2022
It was a pleasure to catch up with @LesokhinMD of @MSKCancerCenter at #ASH25 to hear about a post-hoc analysis of the MagnetisMM-3 trial evaluating the feasibility & safety of prolonged elranatamab interruption in R/R #myeloma.
Watch here: 👉
#MMSM
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis
In this video, Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the results of ...
ow.ly
🎥 Adlette Inati of @lebamericanuni presents findings from the first cohort of the ongoing Phase I/II HIBISCUS Kids study, which investigates the PK activator etavopivat in children & adolescents with #SickleCellDisease:
👉 👈
#ASH25 #Hematology #CTSM
Safety and efficacy of etavopivat in adolescents with SCD: the ongoing HIBISCUS Kids trial
Adlette Inati, MD, Lebanese American University, Blat, Lebanon, discusses safety and efficacy findings from the first ...
ow.ly
Watch our interview from #ASH25 with Lynette Chee of @PeterMacCC to hear updated results from an ongoing Phase II trial of elritercept in patients with transfusion-dependent LR-MDS.🩸
Click here: 👉
#MDSsm #CTSM #TrialUpdate #HemOnc
Updated results from a Phase II trial of elritercept in LR-MDS
Lynette Chee, MBBS, PhD, The Royal Melbourne Hospital/Peter MacCallum Cancer Centre, Melbourne, Australia, shares updated ...
ow.ly
Our latest podcast dives into key multiple myeloma updates from #ASH25 🩸
From redefining functional high-risk disease to CAR-T and T-cell engagers.
🎧 Listen here:
Featuring Luciano Costa (@End_myeloma), Nisha Joseph (@nishjo76), Shambavi Richard,
Top updates in myeloma from ASH 2025: the RedirecTT-1 and MajesTEC-3 trials, dual-targeting CAR-T,...
This podcast features key updates in multiple myeloma from ASH 2025. Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham,...
ow.ly
Could progression of disease within 36 months (POD36) of starting first-line targeted therapy be used as a clinical tool to identify high-risk patients with CLL?🩸
@hampel_p of @MayoClinic provides insight into this in a video interview from #ASH25:
🎥
POD36 as a prognostic marker and clinical tool in frontline CLL
In this interview, Paul Hampel, MD, Mayo Clinic, Rochester, MN, highlights that progression of disease within 36 mon...
ow.ly
